macro

Court approves Bayer's up to $7.25 billion Roundup settlement

A Missouri judge approved Bayer's settlement of up to $7.25 billion covering nearly all U.S. Roundup cancer claims. About 200 federal cases remain pending.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

A Missouri judge has approved Bayer's settlement of up to $7.25 billion. It covers nearly all current and future U.S. claims that Roundup caused cancer, according to TradingView. About 200 federal cases are still pending, and Bayer has not admitted any liability.

Bayer said the settlement excludes roughly 200 pending federal cases. The company pointed to a recent U.S. Supreme Court ruling that limits state failure-to-warn claims as a line of defense.

why it matters

For investors, the main effect is less uncertainty around the company's largest legal risk. A settlement with a capped payout range typically supports a company's shares, though the remaining federal cases keep some risk in place and may still weigh on the stock.

market impact

Bayer shares: lower litigation risk supports the stock

  • Bayer shares pressure up — reduced uncertainty over Roundup cancer lawsuits

tags

instruments

BAYN

sources

  1. Key facts: Bayer deal approved; 200 cases pending; SUNHARBO launches — TradingView, 21 November 2026 at 06:00 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗